异基因移植后复发霍奇金淋巴瘤患者使用纳武利尤单抗的疗效与耐受性
该回顾性研究评估纳武利尤单抗单药治疗20例异基因造血细胞移植(allo-HCT)后复发霍奇金淋巴瘤(HL)患者的疗效与毒性。纳武利尤单抗启动后6例(30%)发生移植物抗宿主病(GVHD),均既往有急性GVHD史,其中2例死于GVHD。总体缓解率为95%,中位随访370天时1年无进展生存率为58.2%(95%CI,33.1%-76.7%),总生存率为78.7%(95%CI,52.4%-91.5%)。作者认为,与标准方案相比,纳武利尤单抗有效且安全性可接受。
要点
- 20例allo-HCT后复发HL患者接受纳武利尤单抗单药治疗,总体缓解率为95%。
- 纳武利尤单抗启动后6例(30%)发生GVHD,均有既往急性GVHD史,其中2例死于GVHD。
- 中位随访370天时,1年无进展生存率为58.2%(95%CI,33.1%-76.7%),总生存率为78.7%(95%CI,52.4%-91.5%)。
核心结论
- 作者认为,与这一适应证的标准选择相比,纳武利尤单抗有效且安全性可接受。
研究设计与样本
- 回顾性评估纳武利尤单抗单药治疗20例异基因造血细胞移植(allo-HCT)后复发霍奇金淋巴瘤(HL)患者的疗效与毒性。
主要发现
- 纳武利尤单抗启动后6例患者(30%)发生GVHD,全部6例均有既往急性GVHD史。
- 纳武利尤单抗诱导的GVHD患者接受急性GVHD标准治疗;2例死于GVHD,1例死于疾病进展,1例死于第二次allo-HCT相关并发症。
- 总体缓解率为95%。
- 中位随访370天时,1年无进展生存率为58.2%(95%CI,33.1%-76.7%),总生存率为78.7%(95%CI,52.4%-91.5%)。
- 在13例仍处于缓解的患者中,6例仅接受单次纳武利尤单抗给药,7例仍在继续纳武利尤单抗治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Allogeneic hematopoietic cell transplantation (allo-HCT) is indicated for patients with relapsed or refractory Hodgkin lymphoma (HL). Although long-term disease control can be achieved, relapse is still frequent. The programmed cell death protein 1 (PD-1) pathway-blocking antibody nivolumab has shown substantial therapeutic activity and an acceptable safety profile in patients with relapsed or refractory HL who did not receive allo-HCT. However, PD-1 blocking strategy can increase the risk of graft-versus-host disease (GVHD) in murine models. We retrospectively assessed the efficacy and toxicity of nivolumab as a single agent in 20 HL patients relapsing after allo-HCT. GVHD occurred in 6 patients (30%) after nivolumab initiation. All 6 patients had prior history of acute GVHD. The patients with nivolumab-induced GVHD were managed by standard treatment for acute GVHD. Two patients died as a result of GVHD, 1 of progressive disease and 1 of complications related to a second allo-HCT. Overall response rate was 95%. At a median follow-up of 370 days, the 1-year progression-free survival rate was 58.2% (95% CI, 33.1%-76.7%) and the overall survival rate was 78.7% (95% CI, 52.4%-91.5%). Among 13 patients still in response, 6 received a single dose of nivolumab and 7 remain on nivolumab. Compared with standard options for this indication, our results show that nivolumab is effective with an acceptable safety profile.
引用
- Herbaux C, Gauthier J, Brice P, et al. Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma. Blood. 2017. PMID: 28270452. doi:10.1182/blood-2016-11-749556
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。